Chapter 3: Pharmacodynamics — Module 2: Dose-Response Relationships, Therapeutic Index and Concentration-Effect Analysis
1. Which of the following pharmacodynamic parameters is the correct measure of a drug's potency?
A) EC50 -- the drug concentration producing 50% of its maximum effect, reflecting how much drug is required to achieve a given level of pharmacological activity; a lower EC50 indicates greater potency (less drug needed for the same effect)
B) Emax -- the maximum biological effect the drug produces regardless of dose, reflecting intrinsic efficacy rather than the concentration required to produce it
C) Bmax -- the total receptor density in a tissue, measured by radioligand saturation binding assays, reflecting receptor abundance rather than drug pharmacodynamic potency
D) TD50 -- the dose producing toxicity in 50% of a population, which determines the upper limit of the therapeutic range rather than the drug's pharmacodynamic potency
E) The Hill coefficient n -- which describes the slope of the concentration-effect curve and determines the steepness of the sigmoidal dose-response relationship rather than the position of the curve on the concentration axis
ANSWER: A
Rationale:
Potency refers to the amount of drug required to produce a given pharmacological effect -- a more potent drug produces the same effect at a lower concentration than a less potent drug. EC50 is the standard quantitative measure of potency: it is the drug concentration at which 50% of the maximum pharmacological effect is achieved, derived from the sigmoidal Emax (Hill) equation. A drug with EC50 of 1 nM is more potent than a drug with EC50 of 1 micromolar, because tenfold less drug is needed to achieve any specified level of effect. Potency and efficacy are distinct pharmacodynamic concepts and must not be confused: efficacy refers to the maximum effect a drug can produce (Emax), which is determined by intrinsic efficacy and is independent of potency. Two drugs can have the same Emax (same efficacy) but very different EC50 values (different potency), or the same EC50 but different Emax values. Clinically, potency determines dose -- a more potent drug can be given in smaller amounts.
Option B: Option B is incorrect -- Emax measures efficacy (the maximum achievable effect), not potency; a drug with high Emax can be a weak drug if it requires very high concentrations to achieve that maximum.
Option C: Option C is incorrect -- Bmax measures total receptor density in a binding assay and is a tissue property, not a drug potency parameter.
Option D: Option D is incorrect -- TD50 measures the dose producing toxicity in 50% of a test population, which is a toxicological endpoint relevant to the therapeutic index rather than to pharmacodynamic potency.
Option E: Option E is incorrect -- the Hill coefficient describes the steepness of the concentration-effect relationship (cooperativity) and determines how sharply the response changes around the EC50; it does not determine potency.
2. Which of the following drugs has a narrow therapeutic index (NTI) and requires therapeutic drug monitoring (TDM) in clinical practice?
A) Amoxicillin, which has a wide therapeutic index and requires no routine TDM in standard adult dosing because the margin between effective and toxic concentrations is very large
B) Atorvastatin, which has a wide therapeutic margin and is dosed empirically based on lipid response rather than plasma drug concentration monitoring
C) Metformin, which has a very wide therapeutic index and is dose-adjusted based on clinical response and renal function rather than serum drug level monitoring
D) Lisinopril, which has a predictable dose-response relationship and wide safety margin requiring only blood pressure and renal function monitoring rather than serum drug concentration measurement
E) Lithium, which has a narrow therapeutic index requiring serum level monitoring to maintain concentrations in the therapeutic range of 0.6-1.2 mEq/L; concentrations below this range produce inadequate mood stabilization while concentrations above 1.5 mEq/L produce toxicity including tremor, ataxia, confusion, and at levels above 2.0 mEq/L, seizures and cardiac arrhythmias
ANSWER: E
Rationale:
The therapeutic index (TI) quantifies the margin between effective and toxic drug concentrations. Drugs with a narrow TI have a small margin between the concentration producing therapeutic effect and the concentration producing toxicity -- small changes in dose or drug exposure can move a patient from the therapeutic range into toxicity. Lithium is the prototypical narrow TI drug in psychiatry. Its therapeutic plasma concentration range for bipolar disorder maintenance is 0.6-1.2 mEq/L (some guidelines accept up to 1.0 mEq/L for maintenance). Concentrations above 1.5 mEq/L produce early toxicity (tremor, nausea, diarrhea, ataxia); above 2.0 mEq/L produce serious toxicity including seizures, cardiac conduction abnormalities, and irreversible neurological damage; above 3.0 mEq/L can be fatal. Because lithium has linear pharmacokinetics and is entirely renally cleared, factors affecting renal function (dehydration, NSAIDs, ACE inhibitors, thiazide diuretics, salt restriction) can raise lithium levels unpredictably, making regular TDM essential. Other classic NTI drugs requiring TDM include digoxin, phenytoin, warfarin, vancomycin, aminoglycosides, cyclosporine, tacrolimus, and methotrexate.
Option A: Option A is incorrect -- amoxicillin has a wide TI; beta-lactam antibiotics are generally safe across a broad dose range with toxicity rare at therapeutic doses.
Option B: Option B is incorrect -- statins have a wide therapeutic margin; dose adjustments are based on LDL-C response and statin-associated muscle symptoms, not plasma drug concentration.
Option C: Option C is incorrect -- metformin has a very wide TI; the main safety concern (lactic acidosis) relates to renal function thresholds for use, not serum metformin levels.
Option D: Option D is incorrect -- lisinopril and ACE inhibitors have a wide therapeutic margin; monitoring is for pharmacodynamic effects (blood pressure, renal function, potassium) rather than drug concentration.
3. In a quantal dose-response curve, the ED50 represents which of the following?
A) The dose producing 50% of the maximum pharmacological effect in a single patient -- the standard measure of potency in graded dose-response analysis
B) The midpoint of the therapeutic concentration range -- halfway between the minimum effective concentration and the minimum toxic concentration for a drug in a population
C) The dose producing the desired all-or-none response in 50% of the population -- the median effective dose in a quantal analysis where each individual either responds or does not respond at a given dose; the ED50 is the dose at which half the population achieves the defined therapeutic endpoint
D) The dose at which 50% of receptors are occupied -- equivalent to the Kd when spare receptors are absent, making it interchangeable with binding affinity in population pharmacodynamics
E) The dose at which the drug transitions from first-order to zero-order kinetics in the population, reflecting saturation of metabolic capacity at concentrations that are effective in 50% of subjects
ANSWER: C
Rationale:
Quantal dose-response curves differ fundamentally from graded dose-response curves. A graded dose-response curve plots the magnitude of response (e.g., blood pressure reduction in mmHg) against drug concentration in a single subject or tissue preparation. A quantal dose-response curve plots the cumulative frequency of an all-or-none response (e.g., seizure suppression, sleep induction, antihypertensive response achieving a defined blood pressure target) against dose in a population. Each individual either achieves the defined endpoint or does not -- there is no intermediate. The ED50 from a quantal curve is the dose at which 50% of the population achieves the defined all-or-none response -- the median effective dose. This is a population statistic, not an individual pharmacodynamic parameter. The quantal ED50 depends on the biological variability in drug sensitivity across individuals (pharmacogenomics, body composition, disease state, age) and is used to construct the therapeutic index (TI = TD50/ED50) where TD50 is the dose producing a defined toxic endpoint in 50% of the population.
Option A: Option A is incorrect -- the dose producing 50% of maximum effect in a single subject is the EC50 from a graded dose-response curve, not the quantal ED50; these are related but conceptually distinct parameters.
Option B: Option B is incorrect -- the midpoint of the therapeutic concentration range is a pharmacokinetic concept; it is not the definition of ED50 in quantal analysis.
Option D: Option D is incorrect -- the dose at which 50% of receptors are occupied corresponds to the Kd (in binding terms) or EC50 (in functional terms); the quantal ED50 is a population-level parameter that reflects the distribution of drug sensitivity, not receptor occupancy.
Option E: Option E is incorrect -- the transition from first-order to zero-order kinetics is a pharmacokinetic phenomenon related to metabolic enzyme saturation; it has no relationship to the quantal ED50.
4. The therapeutic index is calculated as which of the following ratios?
A) Emax / EC50 -- the ratio of maximum achievable efficacy to the potency required to reach half-maximal effect, reflecting the overall pharmacodynamic efficiency of the drug
B) TD50 / ED50 -- the ratio of the dose producing toxicity in 50% of the population to the dose producing the desired therapeutic response in 50% of the population; a larger TI indicates a wider margin between therapeutic and toxic doses
C) Kd / EC50 -- the ratio of binding affinity to functional potency, reflecting the degree of receptor reserve amplification in the tissue where the drug produces its effect
D) LD50 / TD50 -- the ratio of the lethal dose to the toxic dose, quantifying the margin between drug-induced toxicity and lethality rather than the margin between efficacy and toxicity
E) ED50 / TD50 -- the inverse of the standard definition, expressing how close the therapeutic dose is to the toxic dose as a fraction less than 1.0
ANSWER: B
Rationale:
The therapeutic index (TI) is the fundamental pharmacodynamic measure of a drug's safety margin -- how much room exists between the dose that produces the desired therapeutic effect and the dose that produces toxicity. It is calculated as TI = TD50 / ED50, where TD50 is the dose producing a defined toxic endpoint in 50% of the population and ED50 is the dose producing the desired therapeutic endpoint in 50% of the population. Both TD50 and ED50 are derived from quantal dose-response curves in population studies. A TI of 10 means that the toxic dose is 10 times the effective dose -- a comfortable margin. A TI of 2 means the toxic dose is only twice the effective dose -- a narrow margin requiring careful dosing and monitoring. The therapeutic index is not the same as the therapeutic window or therapeutic range, which refer to the plasma concentration range associated with efficacy and acceptable tolerability in clinical practice. For drugs with very narrow TI (lithium, digoxin, phenytoin, warfarin, aminoglycosides), small changes in dose, renal function, drug interactions, or patient physiology can push drug concentrations from therapeutic to toxic, requiring TDM.
Option A: Option A is incorrect -- Emax/EC50 has no standard pharmacodynamic name and does not measure the safety margin between efficacy and toxicity; it conflates an efficacy parameter with a potency parameter.
Option C: Option C is incorrect -- Kd/EC50 reflects receptor reserve (when this ratio is greater than 1, receptor reserve is present), not therapeutic index.
Option D: Option D is incorrect -- LD50/TD50 measures the margin between toxicity and lethality, which is a different safety parameter used in preclinical toxicology; the TI in clinical pharmacology uses TD50, not LD50, in the numerator.
Option E: Option E is incorrect -- ED50/TD50 is the inverse of the correct formula; this ratio would be less than 1 for a drug with any safety margin, and a larger value would paradoxically indicate a narrower therapeutic index.
5. A Hill coefficient (n) greater than 1 in the Hill equation indicates which of the following?
A) Negative cooperativity -- receptor binding at one site reduces affinity at other sites, producing a shallower-than-hyperbolic concentration-effect curve and a Hill coefficient less than 1
B) Non-linear (zero-order) pharmacokinetics producing disproportionate plasma concentration increases at higher doses, which steepens the observed concentration-effect curve in population studies
C) A drug with multiple active metabolites that summate their effects, producing a steeper apparent concentration-effect curve than the parent compound alone would generate at each concentration
D) Positive cooperativity -- binding of the drug or ligand at one site increases the affinity or probability of binding and activation at adjacent sites, producing a sigmoidal concentration-effect curve that is steeper than a simple hyperbola; for ion channels and some receptor systems, n greater than 1 also reflects the requirement for multiple simultaneous ligand binding events to open the channel or activate the receptor
E) A receptor system where spare receptors amplify potency, compressing the EC50 (the concentration producing 50% of maximum effect) well below the Kd and producing an apparently steeper relationship between concentration and occupancy
ANSWER: D
Rationale:
The Hill equation (also called the sigmoidal Emax model) describes the concentration-effect relationship as: Effect = Emax × C^n / (EC50^n + C^n), where n is the Hill coefficient. When n = 1, the equation reduces to a simple hyperbola (the Michaelis-Menten or Langmuir isotherm), producing a gradual graded response. When n > 1, the concentration-effect curve is steeper than a hyperbola -- the transition from low effect to high effect occurs over a narrower concentration range. Mechanistically, n > 1 indicates positive cooperativity: occupancy or activation at one binding site increases the probability or affinity of subsequent binding events at adjacent sites. This is well-characterized in oligomeric receptor systems such as nicotinic acetylcholine receptors, where multiple acetylcholine binding events are required for channel opening. It also applies to hemoglobin oxygen binding (Hill coefficient approximately 2.8), where O2 binding to one subunit increases O2 affinity at other subunits. For clinical pharmacology, a high Hill coefficient means the response switches sharply from minimal to maximal over a narrow concentration range -- drugs with n > 2 behave almost like on-off switches. When n < 1, negative cooperativity is indicated -- binding at one site reduces affinity at others.
Option A: Option A is incorrect -- negative cooperativity produces n less than 1, the opposite of what is asked.
Option B: Option B is incorrect -- non-linear pharmacokinetics (zero-order) affects the relationship between dose and plasma concentration, not the pharmacodynamic Hill coefficient which describes the concentration-effect relationship independently.
Option C: Option C is incorrect -- multiple active metabolites would produce complex pharmacodynamics but are not the mechanistic basis of the Hill coefficient; n reflects cooperativity at the receptor level.
Option E: Option E is incorrect -- receptor reserve affects EC50 relative to Kd but does not change the Hill coefficient; spare receptors shift the curve leftward but do not steepen it beyond n=1.
6. Which of the following correctly identifies a drug whose narrow therapeutic index is complicated specifically by non-linear (zero-order, saturable) pharmacokinetics at therapeutic plasma concentrations?
A) Phenytoin, which has a narrow therapeutic index and at therapeutic plasma concentrations saturates its own hepatic CYP2C9-mediated metabolism; above the saturation point, small dose increases produce disproportionately large rises in plasma concentration because the elimination pathway is operating at maximum capacity and excess drug accumulates; this makes phenytoin dose titration uniquely hazardous and unpredictable
B) Warfarin, which has a narrow TI but follows standard first-order pharmacokinetics, with dose-response unpredictability arising from pharmacogenomic variability in CYP2C9 and VKORC1 (vitamin K epoxide reductase complex subunit 1) rather than kinetic non-linearity
C) Digoxin, which has a narrow TI and a prolonged half-life but follows first-order kinetics throughout the therapeutic range, with toxicity risk driven by electrolyte disturbances and renal function changes rather than kinetic saturation
D) Lithium, which has a narrow TI and is renally cleared without hepatic metabolism, producing concentration-dependent toxicity through a pharmacodynamic mechanism rather than through non-linear pharmacokinetics
E) Aminoglycosides, which exhibit non-linear pharmacokinetics only at supratherapeutic concentrations associated with nephrotoxicity, not within the therapeutic range where first-order kinetics apply
ANSWER: A
Rationale:
Phenytoin is the classic example of a clinically important drug with saturable (Michaelis-Menten, zero-order) pharmacokinetics within its therapeutic range. At low plasma concentrations, phenytoin elimination follows first-order kinetics -- elimination is proportional to concentration. However, as plasma concentrations approach the therapeutic range (10-20 mg/L), the CYP2C9 (and to a lesser extent CYP2C19) enzyme system responsible for phenytoin's hepatic hydroxylation becomes saturated. At saturation, the elimination pathway is operating at its maximum velocity (Vmax) and can process no additional drug per unit time regardless of how much more drug is present. Any dose increase above the saturation point produces a disproportionately large rise in plasma concentration -- a small dose increment can push plasma levels from therapeutic (15 mg/L) to severely toxic (35 mg/L). This is why phenytoin dose adjustments must be made in small increments (typically 25-50 mg at a time) as the therapeutic range is approached, and why phenytoin TDM is essential. Combined with its narrow TI and significant drug interaction potential (many drugs inhibit or induce CYP2C9), phenytoin management is one of the most pharmacologically demanding tasks in clinical practice.
Option B: Option B is incorrect -- warfarin's unpredictability is pharmacogenomic and pharmacodynamic rather than kinetic; it follows first-order kinetics.
Option C: Option C is incorrect -- digoxin follows first-order kinetics; its toxicity is driven by pharmacodynamic sensitization (hypokalemia, renal function) rather than kinetic non-linearity.
Option D: Option D is incorrect -- lithium is renally cleared by first-order kinetics; its narrow TI reflects a narrow pharmacodynamic window rather than non-linear kinetics.
Option E: Option E is incorrect -- aminoglycosides follow first-order kinetics within the therapeutic range; the extended interval dosing strategy exploits concentration-dependent killing, not kinetic non-linearity.
7. The Emax of a drug is best described as which of the following?
A) The drug concentration at which effect is first detectable above baseline -- the threshold concentration below which no pharmacological response occurs regardless of receptor occupancy
B) The dose producing the maximum tolerated effect -- the highest dose achievable before dose-limiting toxicity supervenes, determined by the drug's therapeutic index in clinical use
C) The maximum receptor occupancy the drug achieves at saturation -- equivalent to Bmax when all available receptors are occupied by drug molecules at very high concentrations
D) The concentration at which the dose-response curve reaches its steepest slope -- the inflection point of the sigmoidal Hill curve where incremental concentration produces the greatest incremental effect
E) The maximum biological effect the drug can produce regardless of dose, determined by the drug's intrinsic efficacy at its receptor; Emax is a ceiling effect -- increasing drug concentration or dose beyond receptor saturation produces no additional effect; full agonists have high Emax while partial agonists have a lower Emax that cannot be exceeded regardless of concentration
ANSWER: E
Rationale:
Emax is the pharmacodynamic parameter that quantifies the maximum effect a drug can produce at its target receptor, achieved when receptors are fully occupied and responding at their maximum capacity. It is the plateau of the sigmoidal concentration-effect curve -- the ceiling beyond which no additional drug concentration produces additional effect. Emax is determined by the drug's intrinsic efficacy (the capacity to activate the receptor once bound) and is independent of potency (EC50). The distinction between full agonists and partial agonists is defined by their Emax: a full agonist produces maximum receptor activation and achieves the tissue's maximum response capacity; a partial agonist, despite binding the same receptor, produces submaximal receptor activation and has a lower Emax that represents an absolute ceiling. No amount of partial agonist can exceed its own Emax. This is clinically important: buprenorphine as a partial mu-opioid agonist has a ceiling effect for respiratory depression (protective in overdose relative to full agonists) but also a ceiling for analgesia (limiting its utility in severe pain).
Option A: Option A is incorrect -- the threshold concentration is a separate pharmacodynamic concept; Emax refers to the maximum, not the minimum detectable, effect.
Option B: Option B is incorrect -- the maximum tolerated dose is a clinical and toxicological endpoint; Emax is a pharmacodynamic parameter describing receptor-mediated maximum effect, independent of tolerability.
Option C: Option C is incorrect -- Bmax is a receptor binding parameter (total receptor density), not a pharmacodynamic efficacy measure; receptor saturation by drug does not equal Emax unless the drug is a full agonist with high intrinsic efficacy.
Option D: Option D is incorrect -- the steepest slope of the sigmoidal curve occurs at the EC50, not at Emax; Emax is the asymptote of the curve, not its inflection point.
8. For which of the following drugs is monitoring of serum electrolytes -- specifically potassium -- a recognized component of toxicity surveillance, and why?
A) Lithium, where hypokalemia is the primary driver of drug toxicity and must be corrected before initiating therapy to prevent cardiac arrhythmias from the combined effects of lithium and low potassium on cardiac conduction
B) Phenytoin, where hypokalemia shifts the dose-response curve for cardiac sodium channel blockade leftward, increasing phenytoin's cardiac toxicity risk at any given plasma concentration in hypokalemic patients
C) Digoxin, where hypokalemia increases digoxin binding to the Na/K-ATPase pump, reduces the threshold for digoxin-induced cardiac toxicity, and sensitizes cardiac tissue to digoxin's arrhythmogenic effects; maintaining normokalemia is a cornerstone of digoxin toxicity prevention
D) Aminoglycosides, where hypokalemia is the primary nephrotoxicity biomarker and its development signals early tubular injury requiring dose reduction or drug discontinuation
E) Warfarin, where hypokalemia directly alters the synthesis rate of vitamin K-dependent clotting factors through effects on hepatic gamma-carboxylase enzyme activity, unpredictably altering INR in anticoagulated patients
ANSWER: C
Rationale:
Digoxin exerts its positive inotropic effect by inhibiting the Na/K-ATPase pump on cardiac myocytes, causing intracellular sodium accumulation, which reduces Na/Ca exchange, leading to increased intracellular calcium and enhanced contractility. Potassium is a critical modulator of this mechanism because K+ and digoxin compete for binding at the same site on the extracellular domain of Na/K-ATPase. When serum potassium is low (hypokalemia), less potassium is available to compete with digoxin for the enzyme binding site, and digoxin binds more avidly -- effectively increasing the pharmacodynamic effect at any given plasma digoxin concentration. The consequence is that hypokalemia dramatically lowers the threshold for digoxin toxicity: a patient with a digoxin level of 1.5 ng/mL who develops hypokalemia from diuretic therapy may experience serious ventricular arrhythmias even though their digoxin level remains within the conventional therapeutic range. This is why loop diuretics and thiazide diuretics -- which are frequently co-prescribed with digoxin in heart failure -- require careful potassium monitoring. Hypokalemia, hypomagnesemia, and hypercalcemia all increase digoxin toxicity risk through pharmacodynamic sensitization.
Option A: Option A is incorrect -- lithium toxicity is not driven by hypokalemia; lithium's narrow TI reflects its pharmacodynamic window for CNS effects, not a potassium-dependent mechanism.
Option B: Option B is incorrect -- phenytoin's toxicity is not modulated by hypokalemia through a leftward shift of its dose-response curve; phenytoin toxicity (nystagmus, ataxia, drowsiness) is concentration-dependent and independent of potassium status.
Option D: Option D is incorrect -- aminoglycoside nephrotoxicity is monitored through serum creatinine and urine output, not hypokalemia; hypokalemia can occur with aminoglycoside use but is not the primary toxicity biomarker.
Option E: Option E is incorrect -- warfarin's INR is not directly affected by hypokalemia; clotting factor synthesis depends on vitamin K availability and CYP2C9 activity, not on potassium-dependent hepatic enzyme modulation.
ANSWER KEY: Q1=A Q2=E Q3=C Q4=B Q5=D Q6=A Q7=E Q8=C
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.